NCT05280509: An ongoing trial by Telios Pharma, Inc.
This trial is ongoing. It must report results 10 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05280509 |
|---|---|
| Title | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With Ruxolitinib in Janus-associated Kinase Inhibitor (JAKi) Treatment-Naïve Myelofibrosis (MF) Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 9, 2022 |
| Completion date | Oct. 31, 2025 |
| Required reporting date | Oct. 31, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |